title: The Budget Impact of Duoresp® Spiromax® (Budesonide + Formoterol Fumarate Dihydrate) Compared With Symbicort® Turbohaler® for the Management of Asthma and Chronic Obstructive Pulmonary Disease in the United Kingdom: Impact on Health Care Costs and Inhalation Technique.
authors.affiliation: Covance Inc., London, UK.
authors.forename: A
authors.initials: A
authors.lastname: Lewis
authors.affiliation: Covance Inc., London, UK.
authors.forename: M
authors.initials: M
authors.lastname: Blackney
authors.affiliation: Teva Pharmaceuticals Europe B. V, Amsterdam, The Netherlands.
authors.forename: S
authors.initials: S
authors.lastname: Torvinen
authors.affiliation: Teva UK Limited, Essex, UK.
authors.forename: J
authors.initials: J
authors.lastname: Holmes
authors.affiliation: Teva UK Limited, Essex, UK.
authors.forename: M
authors.initials: M
authors.lastname: Osborne
authors.affiliation: Teva UK Limited, Essex, UK.
authors.forename: J
authors.initials: J
authors.lastname: Dale
authors.affiliation: Teva UK Limited, Essex, UK.
authors.forename: S
authors.initials: S
authors.lastname: Chandler
authors.affiliation: Teva Pharmaceuticals Europe B. V, Amsterdam, The Netherlands.
authors.forename: A
authors.initials: A
authors.lastname: Plich